3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Peritoneal Neoplasms
2
Gastric Adenocarcinoma
2
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Ovarian Epithelial Cancer Recurrent
1
Neoplasms
1
Neoplasm Metastasis
1
Locally Advanced Gastric Cancer
1
Krukenberg Tumor
1
Fallopian Tube Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Interventions
Paclitaxel
22
Bevacizumab
20
Carboplatin
19
liposomal doxorubicin
14
Specimen Handling
14
Magnetic Resonance Spectroscopy
13
olaparib
12
Topotecan
9
Gemcitabine
9
Biopsy
8
pembrolizumab
7
Taxes
6
Immunoglobulin G
6
Disulfides
6
niraparib
4
mirvetuximab soravtansine
4
cediranib
4
Doxorubicin
4
oregovomab
3
Nivolumab
3
Cyclophosphamide
3
sarilumab
2
rucaparib
2
cemiplimab
2
berzosertib
2
adavosertib
2
Oxaliplatin
2
Docetaxel
2
Cisplatin
2
Biosimilar Pharmaceuticals
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fallopian Tube Neoplasms
×
Hyperthermic Intraperitoneal Chemotherapy
×
90 days
×
Clear all
NCT04415944
2026-03-19
HIPEC
Wake Forest University Health Sciences
Phase 2
Completed
10 enrolled